orphan drug – CFN Media

Analyst and Research Coverage Bullish on Cardiol Therapeutics

Cardiol Therapeutics Inc. (Nasdaq: CRDL) (TSX: CRDL) has in some ways burst…

Robin Lefferts
May 1, 2024

Healthcare Stocks

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Topline Results Expected in Q2 2024 This is a Designated News Release.…

Ryan Allway
February 21, 2024

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company’s…

Ryan Allway
February 15, 2024

Is Reducing Fat the Key to Treating Heart Failure?

Everybody knows that excessive fat can lead to a wide variety of…

Robin Lefferts
October 18, 2023

Don Kreski

Robin Lefferts

Ryan Allway

Ryan has been a financial writer for more than a decade, covering…

Cardiol’s Favorable Phase 2 Results Set the Table for Advanced Clinical Trials

Cardiol Therapeutics Inc. (Nasdaq: CRDL) (TSX: CRDL) recently presented excellent…

Robin Lefferts
November 20, 2024

Aduro Clean Technologies Engages Global Leader Zeton for Design and Fabrication of Hydrochemolytic™ Pilot Plant

Milestone Project to Demonstrate Aduro’s Modular, Scalable Solution for Converting…

Ryan Allway
November 19, 2024

IKE Tech LLC and Ispire Technology Inc. Announce Positive Pre-PMTA Submission Meeting with the FDA

Seeks Authorization for Pioneering Point-of-Use Identity and Age Verification…

Ryan Allway
November 18, 2024

Healthcare Stocks

Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Marked and rapid reductions in both pericarditis pain and inflammation maintained…

Ryan Allway
November 18, 2024